Evaluation of the effect of Echinacea syrup on outcome in lower of respiratory infections of COVID-19

The effect of Echinacea syrup on outcome in lower respiratory infections in patients with covid-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130522013423N2

Enrollment

Registered

2022-05-18

Start date

2022-05-15

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. Multisystem inflammatory syndrome associated with COVID-19, unspecified

Interventions

Intervention 1: Intervention group: In addition to applying the routine approaches of the inpatient ward, 5 cc of Echinasea syrup, which is a herbal medicine made by Kimia Daroo factory affiliated to

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Definitive diagnosis of Covid 19 Willingness to participate Evidence of symptoms of lower respiratory infections

Exclusion criteria

Exclusion criteria: Having underlying diseases such as COPD deformity in the chest

Design outcomes

Primary

Measure	Time frame
Symptoms of the infection in the lower respiratory tract. Timepoint: Before and after hospitalization. Method of measurement: Procalcitonin test, chest x-ray.	—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: After discharge. Method of measurement: Determining hospitalization days using patient record.;Re-hospitalization. Timepoint: After discharge. Method of measurement: Number of readmission times.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed-Mousa Mahdizadeh

Mashhad University of Medical Sciences

mahdizadehm@mums.ac.ir+98 51 3859 1511

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026